breast cancer – Oral Cancer News

In an era of rapidly proliferating, precisely targeted treatments, every cancer case has to be played by ear.

Source: www.nytimes.comAuthor: Sidhartha Mukherjee Illustration by Cristiana Couceiro. Photograph by Ansel Adams, via the National Archives, College Park, Md. The bone-marrow biopsy took about 20 minutes. It was 10 o’clock on an unusually chilly morning in New York in April, and Donna M., a self-possessed 78-year-old woman, had flown in from Chicago to see me in my office at Columbia University Medical Center. She had treated herself to orchestra seats for “The Humans” the night before, and was now waiting in the room as no one should be asked to wait: pants down, spine curled, knees lifted to her chest — a grown woman curled like a fetus. I snapped on sterile gloves while the nurse pulled out a bar cart containing a steel needle the length of an index finger. The rim of Donna’s pelvic bone was numbed with a pulse of anesthetic, and I drove the needle, as gently as I could, into the outer furl of bone. A corkscrew of pain spiraled through her body as the marrow was pulled, and then a few milliliters of red, bone-flecked sludge filled the syringe. It was slightly viscous, halfway between liquid and gel, like the crushed pulp of an overripe strawberry. I had been treating Donna in collaboration with my colleague Azra Raza for six years. Donna has a preleukemic syndrome called myelodysplastic syndrome, or MDS, which affects the bone marrow and blood. It is a mysterious disease with few known treatments. Human bone marrow is normally a [...]

Charlotte Parker2016-05-16T16:34:05-07:00May, 2016|Oral Cancer News|

Depressed Head and Neck Cancer Patients Have Lower Survival and Higher Recurrence Risk

Source: www.OncologyNurseAdvisor.comAuthor: Kathy Boltz, PhD Depression is a significant predictor of 5-year survival and recurrence in patients with head and neck cancer, according to a new study published in Pyschosomatic Medicine (doi: 10.1097/PSY.0000000000000256). These findings represent one of the largest studies to report on the impact of depression on cancer survival. Although depression can have obvious detrimental effects on a person's quality of life, its impact on cancer patients is more apparent, explained lead author Eileen Shinn, PhD, assistant professor of Behavioral Science at The University of Texas MD Anderson Cancer Center, in Houston. Increasing evidence shows modest associations between elevated symptoms of depression and greater risk for mortality among patients with lung, breast, ovarian, and kidney cancers. The research team sought to clarify the influence of depression on survival, focusing their analysis on a single cancer type. By limiting the sample set and adjusting for factors known to affect outcome, such as age, tumor size, and previous chemotherapy, they were able to uncover a more profound impact of depression. The researchers followed 130 patients at MD Anderson with newly diagnosed oropharyngeal squamous cell carcinoma (OSCC), a type of cancer in which the tumor originates at the back of the throat and base of the tongue. At the beginning of their radiation therapy, Patients completed a validated questionnaire at the beginning of their radiation therapy to identify symptoms of clinical depression. Researchers monitored the participants, all of whom completed treatment, until their last clinic visit or death, a median period of [...]

Charlotte Parker2015-12-30T18:15:58-07:00December, 2015|Oral Cancer News|

Why groundbreaking new cancer drugs still don’t work for most patients

Source: www.news.doximity.comAuthor: Brady Dennis Immunotherapy, which aims to harness the body's immune system to fight off certain cancers, has received plenty of attention, praise and investment in recent years. Breakthrough treatments for melanoma and other cancers have shown startling results, giving some patients months and often years of life they almost certainly would not otherwise have had. Yet, for all their promise, immune therapies have not produced such dramatic results for the majority of patients. The same drug that causes metastatic melanoma to vanish in one patient might have no effect on another. At best, only one or two patients out of five will respond to immunotherapy treatments -- remarkable numbers compared to past standards, but still far lower than anyone would like. New research published Monday in the journal Nature explores the molecular mechanisms that prevent immunotherapy drugs from working in some patients, and researchers hope the findings will help make the treatments more effective over time. In short, the researchers studied why certain tumors were able to evade immune therapies designed to unleash the body's defenses to fight cancer. They noted that tumors with a high concentration of "T cells," a type of white blood cell essential to the human immune system, were more responsive to the treatments. Tumors with a low number of T cells inside what researchers call the "cancer microenvironment" were far less responsive to the new drugs. "The tumors are acting to protect themselves," said Weiping Zou, a senior author of the study and a professor of surgery, immunology and biology at the University of Michigan's [...]

Charlotte Parker2015-10-30T12:28:18-07:00October, 2015|Oral Cancer News|

SA Developed Melanoma Drug Now Seen Effective in Fighting Lung Cancer

Source: www.woai.comAuthor: News Radio 1200 WOAI Staff Keytruda, a cancer drug developed largely at San Antonio's START Center, has already proven to be effective in treating advanced melanoma to the point that it is the major part of former President Jimmy Carter's treatment. Now, News Radio 1200 WOAI reports Keytruda has been given 'fast track' approval by the FDA for use in treating lung cancer, the leading cause of cancer deaths in the United States. Dr. Amita Patnaik, a researcher and oncologist at START who helped develop the drug, says the impact of Keytruda on lung cancer patients has been amazing. "Close to 40% of those patients will receive a response," she said. "And of those patients who receive a response, about 80% of those patients will have a long term response." The life saving potential of Keytruda in fighting non small cell lung tumors is obvious. An estimated 221,000 Americans are diagnosed with lung cancer each year, and 158,000 die of the disease annually. Dr. Patnaik says Keytruda is becoming the most successful of what are known as 'targeted therapies,' drugs which trigger the body to take action to fight the cancer. She says both melanoma and lung cancer work essentially the same way to undermine the body's defenses. "The commonality between melanoma and lung cancer is there is a supressive effect of the cancer on the immune system." She says Keytruda essentially overrides that supressive effect, prompting the body to restart its natural immune defenses and fight the [...]

Charlotte Parker2015-10-06T11:11:27-07:00October, 2015|Oral Cancer News|

Marilyn Baker: Are some diseases more equal than others?

Source: National Post On Sept. 30, thousands of people will participate in the Run for the Cure marathon. They will raise thousands of dollars for breast cancer research. The Canadian Breast Cancer Foundation website is a sea of pink and purple and shows many further upcoming events where people can get involved in fighting breast cancer: The Nite of Hope auction, garden parties, the Pink Ribbon Charity Ball. The viewer is overwhelmed by the sheer volume of the support. It reminds me of an email I received a few years ago from a dear friend who asked me to pledge support for a breast cancer walkathon. Her personal website stated that “together, we can beat breast cancer.” There were some stats on the disease, plus a little thermometer measuring how her pledges were doing. Seeing the pink ribbons raises many emotions in me. And, to be honest, one of them is anger. Please don’t get me wrong. I have more than a passing interest in breast cancer. I lost a dear sister-in-law to breast cancer. I have friends who live with the illness. I consider myself a lucky breast cancer survivor. So why am I upset? Simple. I’m jealous of all the attention paid to breast cancer when there are so many other cancers that could also benefit from public awareness. All cancers should be a priority. My breast cancer was caught by a screening mammogram. After a biopsy confirmed an invasive lobular carcinoma, I underwent a partial mastectomy and underarm [...]

Charlotte Parker2012-09-14T11:02:30-07:00September, 2012|Oral Cancer News|

When life hands you cancer, make cancer-ade: via lemonade stand, 6yo boy raises $10K for dad’s chemo

Source: Boingboing.net A story making the rounds this week: Drew Cox, a 6 year old boy in Texas, "decided to sell lemonade to help his father with medical bills." His dad, Randy Cox, has a rare form of metastatic cancer, diagnosed a few months ago. The family says Drew's lemonade stand earned more than $10,000. They have an online fundraising site here, where they're trying to raise more. I am currently undergoing chemotherapy for breast cancer, diagnosed about four months ago. When I saw various versions of this story popping up on news sites, several thoughts came to mind. First, hooray for this child. I hope his dad gets the treatment he needs, that the treatment is successful, and that the family doesn't go into debt or have to forego treatment for lack of funds. But second: this is a disgrace. I hate it when stories like this are flogged in media as "feel-good" stories. This story should make America feel ashamed, not feel good. Seriously? A working father gets cancer, and the family has to rely on charity, and a lemonade stand manned by their 6 year old son, to obtain life-sustaining medical treatment? It's not the first such lemonade/chemo-money story to make the rounds in the media, wrapped up in feel-good. When life hands you cancer, the news narrative seems to be, just make cancer-ade! Well, I have cancer. I have insurance. I still pay what is for me a huge out-of-pocket sum, even after my insurance, for [...]

Charlotte Parker2012-04-18T14:54:16-07:00April, 2012|Oral Cancer News|

Which Cancers Are Increasing Among Older Adults?

Source: AARP Cancers of the mouth and throat related to oral sex, as well as thyroid, liver and skin cancers are on the rise among older adults, according to new stats released last week from the American Cancer Society. There was some good news, however. The death rate is down for the well-known major cancers. The society’s Cancer Statistics 2012 report found that overall, cancer deaths dropped by nearly two percent for both men and women from 2004 to 2008. That may sound paltry, but Len Lichtenfeld, M.D., the society’s deputy chief medical officer, says it is more significant than it seems: Many people avoided even hearing the words “you have cancer” because advances in cancer treatment caught problems early, while still in the pre-cancerous stage, he said. The report found that death rates were down for all four major cancers — lung, colorectal, breast and prostate. The biggest drop was for lung cancer, which is down almost 40 percent in the number of men dying from the disease, thanks to fewer Americans smoking. Deaths among women from breast cancer declined 34 percent, mainly because of increases in mammogram screening and a decrease in hormone use for menopause, the ACS report said. On the other hand, some cancers are increasing, particularly among older Americans. According to Medscape News , the ACS found that people 55 to 64 years of age had the highest increase in incidence rates for liver and HPV-related oral cancers; people 65 and older also had an increase in incidence rates [...]

Charlotte Parker2012-01-10T14:48:32-07:00January, 2012|Oral Cancer News|

HPV Vaccine and Premarital-Sex Controversy

Source: The News Tribune Some perspective is needed on the controversy over the Human Papillomavirus (HPV) vaccine that arose after a recent Republican presidential debate. The best way to do that is to take sex out of the equation. Instead of preventing a sexually transmitted disease that can lead to cervical cancer in women and oral cancer in men, let’s say the HPV vaccine guarded against a fictional virus that caused breast cancer and prostate cancer. Wouldn’t most parents jump at the chance to decrease the chances of their children contracting those potentially deadly cancers? Only the most hard-core anti-vaccine holdout would say no. Which gets us back to the sex part of the HPV equation and why some otherwise rational people don’t think children should be inoculated against it. They oppose the HPV vaccine – Cervarix or Gardasil – because they fear that removing one of the consequences of premarital sex would encourage it. It’s a weak argument. The fear of STDs and pregnancy hasn’t put much of a damper on teens having sex, so it’s hard to see why the chance of developing cancer several years down the road would slow them down. They also know that smoking can cause lung cancer, but many still do it. Sometimes parents have to do things to protect kids from themselves – and teens from their hormones. Most young people will not wait until marriage to have sexual relations; parents who think not getting their children vaccinated against HPV will deter [...]

Oral Cancer Foundation News Team - A2011-09-27T10:32:53-07:00September, 2011|Oral Cancer News|

Reirradiation Effective in Post-Radiation Sarcoma

Source: MedScape Today News Reirradiation plus hyperthermia is an effective treatment for radiation-associated sarcoma (RAS) and could even cure some of these rare tumors, a small new study suggests. "The reirradiation plus hyperthermia as we used it appears to be quite successful with a very high response rate and reasonable local control rate," Dr. Geertjan van Tienhoven of the Academic Medical Center in Amsterdam, one of the study's authors, told Reuters Health. RAS develops in areas previously reirradiated with 25 to 80 Gray, usually with a latency period of three years or more, and with a different histology from the original tumor, according to a June 28th online paper in Cancer. Dr. van Tienhoven predicts that "radiation-associated sarcomas are going to be more frequent in the future, because of an increasing prevalence of breast cancer survivors who are at risk, be it a low risk, for RAS." These tumors are usually resected with radical surgery and sometimes adjuvant chemotherapy. To date, according the paper, there haven't been any randomized trials or other prospective studies of reirradiation for RAS. "Many papers and textbooks state that radiation shouldn't be done in these tumors because they are caused by radiation. Indeed it sounds counterintuitive to irradiate again," Dr. van Tienhoven said in an interview. But using hyperthermia with reirradiation allows for a lower radiation dose, he and his coauthors explain. The Academic Medical Center and the Institute Verbeeten have "extensive experience" with this approach, for example in breast cancer recurrence in previously irradiated [...]

Oral Cancer Foundation News Team - A2011-08-09T10:29:53-07:00August, 2011|Oral Cancer News|

New Screening Program for Throat Cancer

Source: The Telegraph Patients would swallow a pill on a string, that expands into a one-inch sponge at the bottom of the throat. This is then draw slowly back up, gently scraping off cells from the wall of the oesophagus. These are then tested for a condition known as Barrett's oesophagus, which can develop into oesophagal cancer over time. Oesophagal cancer is the sixth-most common type in Britain, killing 7,500 people a year. It is often diagnosed when it has advanced, which means survival rates are low: just eight per cent live at least five years from diagnosis, compared to 82 per cent for breast cancer. Researchers at Cambridge University, Cambridge University Hospitals NHS Foundation Trust and the Medical Research Centre are excited because the 'cytosponge' is both cheaper and less invasive than the current testing method, endoscopy. In that, an ear nose and throat expert inserts a tiny camera down the throat to select and remove sample cells. It costs about £400 a time. The team, supported by Cancer Research UK, is now hoping to recruit 1,400 volunteers to compare the accuracy of both methods. Dr Rebecca Fitzgerald, who led the Cambridge-based team that developed the cytosponge test, said: "If this trial is successful it will provide a cheap, safe and highly effective method of identifying people with Barrett’s oesophagus, so they can take steps to reduce their risk of developing cancer. "This would open the doors for a national screening programme, much like those offered for breast, cervical [...]

Oral Cancer Foundation News Team - A2011-07-25T09:31:24-07:00July, 2011|Oral Cancer News|